Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment

Jae Hyup Jung, Dong Woo Shin, Jaihwan Kim, Jong-Chan Lee, Jin-Hyeok Hwang, Jae Hyup Jung, Dong Woo Shin, Jaihwan Kim, Jong-Chan Lee, Jin-Hyeok Hwang

Abstract

Although FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) has been proven efficacious in metastatic pancreatic cancer (MPC), physicians hesitate to administer it due to its hematologic toxicities. We investigated the usefulness of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis. We reviewed electronic medical records of MPC patients with good performance status who were administered FOLFIRINOX as the first-line treatment from 2011 to 2017. The patients were divided into primary G-CSF prophylaxis users (group A) and non-users or therapeutic/secondary users (group B). Cumulative relative dose (cRDI), adverse effects (AEs), and overall survival (OS) were compared. A total of 165 patients (group A (57) vs. group B (108)) were investigated. Intergroup differences in baseline characteristics were not significant, although the cRDI and the number of treatment cycles were both higher in group A than in group B (cRDI: 80.6% vs. 73.9%, p = 0.007; 9 vs. 6 cycles, p = 0.004). Primary G-CSF prophylaxis reduced the risk of neutropenia (55.6% to 31.6%, p = 0.003) and febrile neutropenia (18.5% to 1.8%, p = 0.002) and improved OS (8.8 to 14.7 months; hazard ratio [HR]: 1.766, 95% CI: 1.257-2.481, p = 0.001). When administering FOLFIRINOX for MPC, primary G-CSF prophylaxis could be rationalized to reduced AEs and improve survival; more prospective studies are needed.

Keywords: FOLFIRINOX; G-CSF prophylaxis; pancreatic cancer.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival in primary G-CSF users and non-users.
Figure 2
Figure 2
Overall survival in primary G-CSF users and non-users ((A) non-older patient subgroup; (B) older patient subgroup).

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551.
    1. Rawla P., Sunkara T., Gaduputi V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J. Oncol. 2019;10:10–27. doi: 10.14740/wjon1166.
    1. Neoptolemos J.P., Kleeff J., Michl P., Costello E., Greenhalf W., Palmer H.D. Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat. Rev. Gastroenterol. Hepatol. 2018;15:333–348. doi: 10.1038/s41575-018-0005-x.
    1. Perkhofer L., Ettrich T.J., Seufferlein T. Pancreatic cancer: Progress in systemic therapy. Gastrointest. Tumors. 2014;1:167–179. doi: 10.1159/000380785.
    1. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardière C., et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817–1825. doi: 10.1056/NEJMoa1011923.
    1. Conroy T., Hammel P., Hebbar M., Abdelghani M.B., Wei A.C., Raoul J.L., Choné L., Francois E., Artru P., Biagi J.J., et al. Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 2018;379:2395–2406. doi: 10.1056/NEJMoa1809775.
    1. Liu G.F., Li G.J., Zhao H. Efficacy and toxicity of different chemotherapy regimens in the treatment of advanced or metastatic pancreatic cancer: A network Meta-analysis. J. Cell Biochem. 2018;119:511–523. doi: 10.1002/jcb.26210.
    1. Chin V., Nagrial A., Sjoquist K., O’Connor C.A., Chantrill L., Biankin A.V., Scholten R.J., Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst. Rev. 2018;3:Cd011044. doi: 10.1002/14651858.CD011044.pub2.
    1. Ozaka M., Ishii H., Sato T., Ueno M., Ikeda M., Uesugi K., Sata N., Miyashita K., Mizuno N., Tsuji K., et al. A phase Ii study of modified folfirinox for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2018;81:1017–1023. doi: 10.1007/s00280-018-3577-9.
    1. Yoshida K., Iwashita T., Uemura S., Maruta A., Okuno M., Ando N., Iwata K., Kawaguchi J., Mukai T., Shimizu M. A multicenter prospective phase Ii study of first-line modified folfirinox for unresectable advanced pancreatic cancer. Oncotarget. 2017;8:111346–111355. doi: 10.18632/oncotarget.22795.
    1. Wang Z.Q., Zhang F., Deng T., Zhang L., Feng F., Wang F.H., Wang W., Wang D.S., Luo H.Y., Xu R.H., et al. The efficacy and safety of modified folfirinox as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun. 2019;39:26. doi: 10.1186/s40880-019-0367-7.
    1. Mizrahi J.D., Rogers J.E., Hess K.R., Wolff R.A., Varadhachary G.R., Javle M.M., Shroff R.T., Ho L., Fogelman D.R., Raghav K.P.S., et al. Modified folfirinox in pancreatic cancer patients age 75 or older. Pancreatology. 2020;20:501–504. doi: 10.1016/j.pan.2020.01.005.
    1. Junior U.P.L.S., Rother E.T., Maluf F.C., Bugano D.D.G. Meta-analysis of modified folfirinox regimens for patients with metastatic pancreatic cancer. Clin. Colorectal Cancer. 2018;17:187–197. doi: 10.1016/j.clcc.2018.03.007.
    1. Baldini C., Escande A., Bouché O., el Hajbi F., Volet J., Bourgeois V., Vantroys T.R., Ploquin A., Desauw C., Hebbar M. Safety and efficacy of folfirinox in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. Pancreatology. 2017;17:146–149. doi: 10.1016/j.pan.2016.12.009.
    1. Peter H., Macintyre J., Kawamura C., Maldonado J.C., Ernani V., Loaiza-Bonilla A., Narayanan G., Ribeiro A., Portelance L., Merchan J.R. A retrospective study of neoadjuvant folfirinox in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:1–7.
    1. Moorcraft S.Y., Khan K., Peckitt C., Watkins D., Rao S., Cunningham D., Chau I. FOLFRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: The Royal Marsden experience. Clin. Colorectal Cancer. 2014;13:232–238. doi: 10.1016/j.clcc.2014.09.005.
    1. Lyman G.H., Yau L., Nakov R., Krendyukov A. Overall survival and risk of second malignancies with cancer chemotherapy and G-Csf support. Ann. Oncol. 2018;29:1903–1910. doi: 10.1093/annonc/mdy311.
    1. Lyman G.H., Reiner M., Morrow P.K., Crawford J. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann. Oncol. 2015;26:1452–1458. doi: 10.1093/annonc/mdv174.
    1. Lyman G.H., Dale D.C., Culakova E., Poniewierski M.S., Wolff D.A., Kuderer N.M., Huang M., Crawford J. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: A systematic review and meta-analysis of randomized controlled trials. Ann. Oncol. 2013;24:2475–2484. doi: 10.1093/annonc/mdt226.
    1. Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J. Clin. Oncol. 2007;25:3158–3167. doi: 10.1200/JCO.2006.08.8823.
    1. Lalami Y., Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Crit. Rev. Oncol. Hematol. 2017;120:163–179. doi: 10.1016/j.critrevonc.2017.11.005.
    1. Lee J.C., Kim J.W., Ahn S., Kim H.W., Lee J., Kim Y.H., Paik K.H., Kim J., Hwang J.H. Optimal dose reduction of folfirinox for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Eur. J. Cancer. 2017;76:125–133. doi: 10.1016/j.ejca.2017.02.010.
    1. Sohal D.P.S., Kennedy E.B., Khorana A., Copur M.S., Crane C.H., Garrido-Laguna I., Krishnamurthi S., Moravek C., O’Reilly E.M., Philip P.A., et al. Metastatic pancreatic cancer: Asco clinical practice guideline update. J. Clin. Oncol. 2018;36:2545–2556. doi: 10.1200/JCO.2018.78.9636.
    1. Okusaka T., Ikeda M., Fukutomi A., Ioka T., Furuse J., Ohkawa S., Isayama H., Boku N. Phase Ii study of folfirinox for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321–1326. doi: 10.1111/cas.12501.
    1. Muranaka T., Kuwatani M., Komatsu Y., Sawada K., Nakatsumi H., Kawamoto Y., Yuki S., Kubota Y., Kubo K., Kawahata S., et al. Comparison of efficacy and toxicity of folfirinox and gemcitabine with Nab-paclitaxel in unresectable pancreatic cancer. J. Gastrointest. Oncol. 2017;8:566–571. doi: 10.21037/jgo.2017.02.02.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe